Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019
May 14 2019 - 4:05PM
Business Wire
� Presentations to be webcast on
www.exelixis.com �
Exelixis, Inc. (Nasdaq: EXEL) today announced that the
company will be presenting at the following two investor
conferences on Tuesday, May 21, 2019, in New York:
- UBS Global Healthcare Conference:
Exelixis is scheduled to present at 10:00 AM EDT / 7:00 AM
PDT.
- RBC Capital Markets Global Healthcare
Conference: Exelixis is scheduled to present at 3:05 PM EDT / 12:05
PM PDT.
To access the webcast links, log
onto www.exelixis.com and proceed to the News &
Events / Event Calendar page under the Investors & Media
heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days
following each presentation.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a
commercially successful, oncology-focused biotechnology company
that strives to accelerate the discovery, development and
commercialization of new medicines for difficult-to-treat cancers.
Following early work in model genetic systems, we established a
broad drug discovery and development platform that has served as
the foundation for our continued efforts to bring new cancer
therapies to patients in need. Our discovery efforts have resulted
in four commercially available products,
CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib),
COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and we
have entered into partnerships with leading pharmaceutical
companies to bring these important medicines to patients worldwide.
Supported by revenues from our marketed products and
collaborations, we are committed to prudently reinvesting in our
business to maximize the potential of our pipeline. We are
supplementing our existing therapeutic assets with targeted
business development activities and internal drug discovery – all
to deliver the next generation of Exelixis medicines and
help patients recover stronger and live
longer. Exelixis is a member of Standard & Poor’s
(S&P) MidCap 400 index, which measures the performance of
profitable mid-sized companies. For more information
about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190514006023/en/
Investors Contact:Susan HubbardEVP, Public Affairs
andInvestor RelationsExelixis,
Inc.650-837-8194shubbard@exelixis.com
Media Contact:Hal MackinsFor Exelixis,
Inc.415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024